Addex Therapeutics Ltd (NASDAQ:ADXN – Get Free Report) saw a significant increase in short interest in April. As of April 15th, there was short interest totalling 21,700 shares, an increase of 149.4% from the March 31st total of 8,700 shares. Approximately 2.7% of the company’s shares are short sold. Based on an average trading volume of 17,100 shares, the short-interest ratio is currently 1.3 days.
Addex Therapeutics Price Performance
Shares of NASDAQ ADXN opened at $16.10 on Friday. The company has a market cap of $17.07 million, a P/E ratio of -0.84 and a beta of 1.66. Addex Therapeutics has a 1 year low of $5.00 and a 1 year high of $27.90. The firm has a 50-day simple moving average of $14.55 and a two-hundred day simple moving average of $9.74.
Institutional Trading of Addex Therapeutics
An institutional investor recently raised its position in Addex Therapeutics stock. Armistice Capital LLC boosted its position in Addex Therapeutics Ltd (NASDAQ:ADXN – Free Report) by 103.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 537,000 shares of the company’s stock after purchasing an additional 273,000 shares during the period. Armistice Capital LLC owned approximately 65.33% of Addex Therapeutics worth $206,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 16.14% of the company’s stock.
Addex Therapeutics Company Profile
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for pain, anxiety, and addiction.
Recommended Stories
- Five stocks we like better than Addex Therapeutics
- What Do S&P 500 Stocks Tell Investors About the Market?
- MarketBeat Week in Review – 4/22 – 4/26
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- 3 Stocks Leading the U.S. Agriculture Comeback
- How to Use the MarketBeat Excel Dividend Calculator
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Addex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Addex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
